Squamous Cell Carcinoma Of The Head And Neck – Landscape & Forecast – Disease Landscape & Forecast

The treatment landscape for squamous cell carcinoma of the head and neck (SCCHN) witnessed a major change in 2019 with the approval of Merck & Co.’s Keytruda for untreated recurrent or metastatic SCCHN. For nearly a decade, the EGFR inhibitor Erbitux (Eli Lilly / Merck KGaA) was the cornerstone in the treatment algorithm. Immune checkpoint inhibitors (e.g., Keytruda, Bristol Myers Squibb / Ono Pharmaceutical’s Opdivo) are also prescribed in later lines, where competition is fierce. Although SCCHN has historically been a complex challenge for drug developers, many immuno-oncology treatment approaches and other drug classes are in the late-phase pipeline for both metastatic and early-stage settings. Several agents are positioned to treat the untapped and lucrative locoregionally advanced SCCHN, fueling market growth over the 2020-2030 forecast period.

Questions Answered

  • What is the current treatment algorithm for locoregionally advanced and recurrent or metastatic SCCHN in the major pharmaceutical markets? What are interviewed experts’ views on current and emerging late-phase therapies?
  • How large are the clinically and commercially relevant drug-treatable SCCHN populations, and how will drug-treatment rates change over the 2020-2030 forecast period?
  • What market and patient share can agents in late-phase development for SCCHN expect to secure?
  • What are the key drivers of and constraints on the SCCHN therapy market, and how will these factors change over the 10-year forecast period?

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution Enhancement

Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Squamous Cell Carcinoma Of The Head And Neck - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q4 2021
        • October 2021
      • Q3 2021
        • September 2021
        • August 2021
      • Q2 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q4 2020
        • December 2020
        • November 2020
    • Key Findings
      • SCCHN - Key Findings
        • December 2020
        • November 2020
    • Market Outlook
      • Key Findings
        • Major-Market Share of SCCHN Drug Classes in 2020
        • Major-Market Share of SCCHN Drug Classes in 2030
        • Drug-Treatable Population Share and Major-Market Sales Share in SCCHN in 2020
        • Drug-Treatable Population Share and Major-Market Sales Share in SCCHN in 2030
        • Population Positioning of Therapies in SCCHN
        • SCCHN SWOT Analysis
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for SCCHN?
        • What Factors Are Constraining the Market for SCCHN?
        • Major-Market Sales for SCCHN by Region: 2020-2030
        • Major-Market Sales for SCCHN by Drug Class: 2020-2030
        • Major-Market Sales of Key Therapies for SCCHN: 2020-2030
      • Segment-Specific Trends
        • Patient-Share Dynamics of Key Treatments for Locoregionally Advanced Non-Nasopharyngeal SCCHN in the United States: 2020-2030
        • Major-Market Shares of Drug Classes for Locoregionally Advanced Non-Nasopharyngeal SCCHN: 2020-2030
        • Patient-Share Dynamics of Key Treatments for First-Line Non-Nasopharyngeal SCCHN in the United States: 2020-2030
        • Patient-Share Dynamics of Key Treatments for First-Line Nasopharyngeal SCCHN in the United States: 2020-2030
        • Major-Market Shares of Drug Classes for First-Line Non-Nasopharyngeal SCCHN: 2020-2030
        • Major-Market Shares of Drug Classes for First-Line Nasopharyngeal SCCHN: 2020-2030
        • Patient-Share Dynamics of Key Treatments for Second-Line Non-Nasopharyngeal SCCHN in the United States: 2020-2030
        • Patient-Share Dynamics of Key Treatments for Second-Line Nasopharyngeal SCCHN in the United States: 2020-2030
        • Patient Share Dynamics of Key Therapies in Third-Line Non-Nasopharyngeal SCCHN in the United States: 2020-2030
        • Patient Share Dynamics of Key Therapies in Third-Line Nasopharyngeal SCCHN in the United States: 2020-2030
        • Major-Market Shares of Drug Classes for Second-Line Non-Nasopharyngeal SCCHN: 2020-2030
        • Major-Market Shares of Drug Classes for Third-Line Non-Nasopharyngeal SCCHN: 2020-2030
        • Major-Market Shares of Drug Classes for Second-Line Nasopharyngeal SCCHN: 2020-2030
        • Major-Market Shares of Drug Classes for Third-Line Nasopharyngeal SCCHN: 2020-2030
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
        • Disease Pathophysiology
          • Anatomy, Development, and Progression of SCCHN
          • Anatomy, Development, and Progression of SCCHN
          • Risk Factors Associated with SCCHN
          • Risk Factors Associated with SCCHN
        • Staging and Classification
          • Clinical Staging of SCCHN
          • Definition of TNM Staging Classification for Oral Cavity SCCHN
          • Definition of TNM Staging Classification of Hypopharyngeal SCCHN
          • Definition of TNM Staging Classification of Laryngeal SCCHN
          • TNM Staging System for Classification of Oral Cavity, Hypopharyngeal, and Laryngeal SCCHN
          • Definition of TNM Staging Classification for Oropharyngeal SCCHN
          • TNM Staging System for Classification of Oropharyngeal SCCHN
          • Definition of TNM Staging Classification of Nasopharyngeal SCCHN
          • TNM Staging System for Classification of Nasopharyngeal SCCHN
          • Composite TNM Staging and Treatment Overview of SCCHN
        • Key Pathways and Drug Targets
          • Key Pathways and Drug Targets in SCCHN
          • Immune Checkpoint Activation and Pathways
      • Epidemiology
        • Key Findings
          • Epidemiology Populations
            • Disease Definition
            • Methods
            • Sources Used for Diagnosed Incidence of SCCHN
            • Number of Diagnosed Incident Cases of SCCHN in the Major Pharmaceutical Markets: 2020-2030
            • Number of Diagnosed Incident Cases of SCCHN by Site (Nasopharyngeal vs. Non-Nasopharyngeal): 2020-2030
            • Disease Definition
            • Methods
            • Sources Used for Stage Distribution of SCCHN
            • Number of Diagnosed Incident Cases of SCCHN in the Major Pharmaceutical Markets by Stage: 2020-2030ttttt
            • Disease Definition
            • Methods
            • Sources Used for Recurrent Incidence of SCCHN
            • Metastatic Recurrent Incident Cases of SCCHN in Major Pharmaceutical Markets: 2020-2030
            • SCCHN Patient Flow
            • Sources Used for Drug-Treatable Populations of SCCHN
            • Drug-Treatable Cases of SCCHN (All Histologies): 2020-2030
            • Drug-Treatable Cases of Non-Nasopharyngeal SCCHN: 2020-2030
            • Drug-Treatable Cases of Nasopharyngeal SCCHN: 2020-2030
            • Sources Used for Drug-Treated SCCHN Populations
            • Drug-Treated Cases of SCCHN (All Histologies): 2020-2030
            • Drug-Treated Cases of Non-Nasopharyngeal SCCHN: 2020-2030
            • Drug-Treated Cases of Nasopharyngeal SCCHN: 2020-2030
        • Current Treatment
          • Key Findings
            • Treatment Goals
              • Key Endpoints Used in Clinical Trials for SCCHN
            • Key Current Therapies
              • Overview
              • Current Treatments Used for SCCHN
              • Market Events Influencing the Use of Key Current Therapies in SCCHN
              • Mechanism of Action of Key Current Drugs Used for SCCHN
              • Key Results from Select Clinical Trials Investigating Erbitux for the Treatment of SCCHN
              • Ongoing Clinical Development of Erbitux
              • Key Ongoing Clinical Trials of Erbitux in the Treatment of SCCHN
              • Expert Insight: Erbitux
              • Key Results from Select Clinical Trials Investigating Keytruda for the Treatment of SCCHN
              • Ongoing Clinical Development of Keytruda
              • Key Ongoing Clinical Trials of Keytruda in the Treatment of SCCHN
              • Expert Insight: Keytruda
              • Key Results from Select Clinical Trials Investigating Opdivo for SCCHN
              • Ongoing Clinical Development of Opdivo
              • Key Ongoing Clinical Trials of Opdivo in the Treatment of SCCHN
              • Expert Insight: Opdivo
              • Key Results from Select Clinical Trials Investigating Steboronine for the Treatment of SCCHN
              • Ongoing Clinical Development of Steboronine
              • Expert Insight: Steboronine
              • Key Results from Select Clinical Trials Investigating Akalux for the Treatment of SCCHN
              • Ongoing Clinical Development of Akalux
              • Key Ongoing Clinical Trials of Akalux in the Treatment of SCCHN
              • Expert Insight: Akalux
            • Medical Practice
              • Early-Stage Localized (Stage I/II) SCCHN
              • Locoregionally Advanced (Stage III/IVA/IVB) SCCHN
              • First-Line Recurrent or Metastatic SCCHN
              • Second- and Third-Line Recurrent or Metastatic SCCHN
              • Treatment Guidelines
              • Patient Characteristics Influencing Drug Selection in SCCHN
              • Treatment Decision Tree for Early-Stage Localized (Stage I/II) SCCHN
              • Treatment Decision Tree for Locoregionally Advanced (Stage III/IVA/IVB) SCCHN
              • Treatment Decision Tree for Recurrent or Metastatic SCCHN
          • Unmet Need Overview
            • Current and Future Attainment of Unmet Needs in SCCHN
            • Top Unmet Needs in SCCHN: Current and Future Attainment
          • Emerging Therapies
            • Key Findings
              • Key Emerging Therapies
                • Key Therapies in Development for SCCHN
                • Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of SCCHN
                • Key Results from Select Clinical Trials Investigating Yervoy for the Treatment of SCCHN
                • Analysis of Clinical Development Program for Yervoy
                • Key Ongoing Clinical Trials of Yervoy in the Treatment of SCCHN
                • Expert Insight: Yervoy
                • Expectations for Market Authorization and Sales Opportunity of Yervoy in SCCHN
                • Key Results from Select Clinical Trials Investigating Imfinzi for the Treatment of SCCHN
                • Analysis of Clinical Development Program for Imfinzi
                • Key Ongoing Clinical Trials of Imfinzi in the Treatment of SCCHN
                • Expert Insight: Imfinzi
                • Expectations for Market Authorization and Sales Opportunity of Imfinzi in SCCHN
                • Key Results from Select Clinical Trials Investigating Bavencio for the Treatment of SCCHN
                • Analysis of Clinical Development Program for Bavencio
                • Key Ongoing Clinical Trials of Bavencio in the Treatment of SCCHN
                • Expert Insight: Bavencio
                • Expectations for Market Authorization and Sales Opportunity of Bavencio in SCCHN
                • Key Results from Select Clinical Trials Investigating Tecentriq for the Treatment of SCCHN
                • Analysis of Clinical Development Program for Tecentriq
                • Key Ongoing Clinical Trials of Tecentriq in the Treatment of SCCHN
                • Expert Insights: Tecentriq
                • Expectations for Market Authorization and Sales Opportunity of Tecentriq in SCCHN
                • Key Results from Select Clinical Trials Investigating Monalizumab for the Treatment of SCCHN
                • Analysis of Clinical Development Program for Monalizumab
                • Key Ongoing Clinical Trials of Monalizumab in the Treatment of SCCHN
                • Expert Insight: Monalizumab
                • Expectations for Market Authorization and Sales Opportunity of Monalizumab in SCCHN
                • Key Results From Select Clinical Trials Investigating Toripalimab for the Treatment of SCCHN
                • Analysis of Clinical Development Program for Toripalimab
                • Key Ongoing Clinical Trials of Toripalimab in the Treatment of SCCHN
                • Expert Insight: Toripalimab
                • Expectations for Market Authorization and Sales Opportunity of Toripalimab in SCCHN
                • Key Results from Select Clinical Trials Investigating Penpulimab for the Treatment of SCCHN
                • Analysis of Clinical Development Program for Penpulimab
                • Key Ongoing Clinical Trials of Penpulimab in the Treatment of SCCHN
                • Expectations for Market Authorization and Sales Opportunity of Penpulimab in SCCHN
                • Key Results from Select Clinical Trials Investigating Rovaleucel for the Treatment of SCCHN
                • Analysis of the Clinical Development Program for Rovaleucel
                • Key Ongoing Clinical Trials of Rovaleucel in the Treatment of SCCHN
                • Expert Insight: Rovaleucel
                • Expectations for Market Authorization and Sales Opportunity of Rovaleucel in SCCHN
                • Key Results from Select Clinical Trials Investigating Multikine for the Treatment of SCCHN
                • Analysis of the Clinical Development Program for Multikine
                • Key Ongoing Clinical Trials of Multikine in the Treatment of SCCHN
                • Expert Insight: Multikine
                • Expectations for Market Authorization and Sales Opportunity of Multikine in SCCHN
                • Key Results from Select Clinical Trials Investigating Lenvima for the Treatment of SCCHN
                • Analysis of Clinical Development Program for Lenvima
                • Key Ongoing Clinical Trials of Lenvima in the Treatment of SCCHN
                • Expert Insight: Lenvima
                • Expectations for Market Authorization and Sales Opportunity of Lenvima in SCCHN
                • Key Results from Select Clinical Trials Investigating Xevinapant for the Treatment of SCCHN
                • Analysis of Clinical Development Program for Xevinapant
                • Key Ongoing Clinical Trials of Xevinapant in the Treatment of SCCHN
                • Expert Insight: Xevinapant
                • Expectations for Market Authorization and Sales Opportunity of Xevinapant in SCCHN
                • Key Results from Select Clinical Trials Investigating Buparlisib for the Treatment of SCCHN
                • Analysis of Clinical Development Program for Buparlisib
                • Key Ongoing Clinical Trials of Buparlisib in the Treatment of SCCHN
                • Expert Insight: Buparlisib
                • Expectations for Market Authorization and Sales Opportunity of Buparlisib in SCCHN
                • Key Results from Select Clinical Trials Investigating Tipifarnib for the Treatment of SCCHN
                • Analysis of Clinical Development Program for Tipifarnib
                • Key Ongoing Clinical Trials of Tipifarnib in the Treatment of SCCHN
                • Expert Insight: Tipifarnib
                • Expectation for Market Authorization and Sales Opportunity of Tipifarnib in SCCHN
              • Early-Phase Pipeline Analysis
              • Access and Reimbursement Overview
                • Region-Specific Reimbursement Practices
                  • Key Market Access Considerations in SCCHN: United States
                  • General Reimbursement Environment: United States
                  • Key Market Access Considerations in SCCHN: EU5
                  • General Reimbursement Environment: EU5
                  • Key Market Access Considerations in SCCHN: Japan
                  • General Reimbursement Environment: Japan
              • Appendix
                • SCCHN Bibliography

            launch Related Market Assessment Reports